BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1205 related articles for article (PubMed ID: 18519708)

  • 1. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
    Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
    Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
    Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
    PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
    Mitsiades N; Sung CC; Schultz N; Danila DC; He B; Eedunuri VK; Fleisher M; Sander C; Sawyers CL; Scher HI
    Cancer Res; 2012 Dec; 72(23):6142-52. PubMed ID: 22971343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.
    Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K
    Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
    Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
    Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer.
    Sharifi N; McPhaul MJ; Auchus RJ
    J Investig Med; 2010 Dec; 58(8):938-44. PubMed ID: 21030877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
    Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
    Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
    Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM
    Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracrine androgen biosynthesis in renal cell carcinoma.
    Lee GT; Han CS; Kwon YS; Patel R; Modi PK; Kwon SJ; Faiena I; Patel N; Singer EA; Ahn HJ; Kim WJ; Kim IY
    Br J Cancer; 2017 Mar; 116(7):937-943. PubMed ID: 28253524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.
    Mostaghel EA; Solomon KR; Pelton K; Freeman MR; Montgomery RB
    PLoS One; 2012; 7(1):e30062. PubMed ID: 22279565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.
    Mostaghel EA
    Int J Biol Sci; 2014; 10(6):602-13. PubMed ID: 24948873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.
    Ettinger SL; Sobel R; Whitmore TG; Akbari M; Bradley DR; Gleave ME; Nelson CC
    Cancer Res; 2004 Mar; 64(6):2212-21. PubMed ID: 15026365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
    Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
    Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.
    Montgomery B; Nelson PS; Vessella R; Kalhorn T; Hess D; Corey E
    BMC Cancer; 2010 May; 10():244. PubMed ID: 20509933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
    Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
    Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.